Jco precision oncology.
Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ...
This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: RocheFinal Summary · The impact factor of JCO Precision Oncology is 5.479. · The JCO Precision Oncology is a reputed research journal. · It is published by ...Limit the abstract to 275 words and place it after the title page. Do not use proprietary or trade names in the title or abstract. Case Reports, Commentaries, Editorials, and Correspondence articles do not require abstracts. Write the body of the manuscript as concisely as possible.JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer.
Apr 23, 2020 · PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ...
journal JCO Precision Oncology is the work of co-first authors Natalie Reizine, MD, a Cancer Center member, and Samantha Socco, PharmD, of @UICPharmacy, …15 Mar 2023 ... Elypta study published in JCO Precision Oncology using GAGome to predict and monitor responses of patients with Metastatic Renal Cell ...
Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ...DOI: 10.1200/PO.22.00517 JCO Precision Oncology no. 6 (2022) e2200517. Published online November 12, 2022. PMID: 36370464. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer Sarah E. Coughlin, MD 1. x. Sarah E. Coughlin. Search for articles by this author ...Mar 9, 2022 · This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic …
This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche
DOI: 10.1200/PO.18.00299 JCO Precision Oncology - published online April 25, 2019 PMID: 32914040 Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...DOI: 10.1200/PO.19.00253 JCO Precision Oncology no. 4 (2020) 66-73. Published online February 13, 2020. PMID: 35050730. Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 Patients Junaid Arshad, MD 1. x. Junaid Arshad. Search for articles by this author ...Nov 12, 2022 · PURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ... PURPOSE Next-generation sequencing (NGS) of tumor and germline DNA is foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications. Although few question the importance of NGS in modern oncology care, the process of gathering primary molecular data, integrating it into electronic health …Jan 12, 2023 · PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET ... DOI: 10.1200/PO.19.00253 JCO Precision Oncology no. 4 (2020) 66-73. Published online February 13, 2020. PMID: 35050730. Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 Patients Junaid Arshad, MD 1. x. Junaid Arshad. Search for articles by this author ...DOI: 10.1200/PO.20.00109 JCO Precision Oncology no. 4 (2020) 898-911. Published online July 28, 2020. PMID: 35050760. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of ...
DOI: 10.1200/PO.19.00172 JCO Precision Oncology - published online September 20, 2019 PMID: 32923866. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Roberta La Starza, MD, PhD 1. x. Roberta La Starza. Search for articles by this author ...DOI: 10.1200/PO.22.00580 JCO Precision Oncology no. 7 (2023) e2200580. Published online March 23, 2023. PMID: 36952646. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study Trisha Larkin, MD 1, 2. x. Trisha Larkin. …WebDOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic ProfilingJCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...PURPOSE With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape of precision oncology, which can be challenging for oncologists to navigate alone. METHODS We developed and implemented a precision oncology decision support system, GI TARGET ...May 11, 2022 · DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728 This author is an Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical, GI OnDemand. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe, GI OnDemand. Huma Q. Rana. …
29 Sept 2022 ... Precision medicine in pediatric oncology. ... Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing. JCO Precis ...PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...
JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision …Whereas the OncoKB system is an extensive, comprehensive, and curated precision oncology knowledge base that is capable of supporting precision oncology treatment decisions, it should be noted that universally accepted definitions of actionable alterations are not currently available. 8 More practically, a total of 21% of patients in our cohort ...DOI: 10.1200/PO.18.00401 JCO Precision Oncology - published online June 20, 2019 Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based ResultsDOI: 10.1200/PO.21.00484 JCO Precision Oncology no. 6 (2022) e2100484. Published online October 31, 2022. PMID: 36315916. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology ...WebDOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427. Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma ...Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ... DOI: 10.1200/PO.20.00532 JCO Precision Oncology no. 5 (2021) 1241-1249. Published online August 5, 2021. Published online August 5, 2021. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic ProfilingWeb
Feb 21, 2022 · DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy
Given the high attrition rate of de novo drug discovery and limited efficacy of single-agent therapies in cancer treatment, combination therapy prediction through in silico drug repurposing has risen as a time- and cost-effective alternative for identifying novel and potentially efficacious therapies for cancer. The purpose of this review is to provide an introduction to computational methods ...
DOI: 10.1200/PO.20.00257 JCO Precision Oncology no. 4 (2020) 1393-1402. Published online November 16, 2020. Published online November 16, 2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesAlthough precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to …WebPURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ...JCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ... This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier MedicinesDOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportDOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019WebJul 9, 2021 · PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit ... The liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration-approved single-gene ctDNA assays. The use of plasma-based molecular profiling …DOI: 10.1200/PO.20.00280 JCO Precision Oncology no. 5 (2021) 215-226. Published online January 19, 2021. PMID: 34994597. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) ...Web
Purpose A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with …DOI: 10.1200/PO.20.00060 JCO Precision Oncology no. 4 (2020) 806-817. Published online July 15, 2020. Published online July 15, 2020. Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer ManagementThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …Instagram:https://instagram. sugar free sparkling winewhat is the best malpractice insurance for nurse practitionersoptionsprofitnon conforming mortgage lenders Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to …WebDOI: 10.1200/PO.21.00122 JCO Precision Oncology no. 5 (2021) 1354-1376. Published online August 25, 2021. Published online August 25, 2021. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns how to read candlestick chartbanks that have virtual debit cards DOI: 10.1200/PO.23.00261 JCO Precision Oncology no. 7 (2023) e2300261. Published online October 12, 2023. PMID: 37824797. Computational Advancements in Cancer Combination Therapy Prediction Victoria L. Flanary, BS 1. x. Victoria L. Flanary. Search for articles by this author ... are manual cars still made May 16, 2017 · Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. Methods OncoKB annotates the ... DOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportJCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision …